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Abstract  Askin  tumor  is  an  uncommon  malignant  neoplasm  of  a  neuroectodermic  origin  that
arises from  the  soft  tissues  of  the  thoracopulmonary  wall.  Defined  histologically  by  Askin  and
Rosai in 1979  as  a  malignant  small  round  cell  tumor.  It  is described  within  a  group  of  malignant
neoplasms  with  an  aggressive  behavior.  The  lack  of  clinical  guides  that  establish  a  standardized
management  contributes  to  its  poor  prognosis  and  short  overall  survival.  Once  a  primitive  neu-
roectodermal  tumor  has been  diagnosed,  treatment  will consist  of  a  multimodal  management.
© 2016  Universidad  Auto´noma  de  Nuevo  Leo´n.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is
an open  access  article  under  the  CC BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
Askin  tumor  is  an uncommon  malignant  neoplasm  of  a neu-
roectodermal  origin  that arises  from  the  soft  tissues  of the
thoraco-pulmonary  wall.1 Histologically  designated  by  Askin
and  Rosai  in 1979  as  a malignant  small  round  cell tumor,2 it
is  described  within  a group  of  malignant  neoplasms  with  an
aggressive  behavior,  classified  by  the World  Health  Organiza-
tion (WHO)  in 2002  as  Ewing’s  Sarcoma/Peripheral  Primitive
Neuroectodermal  Tumor  (SE/PPNETS),  organizing  tumors  of
neuroectodermal,  bone  and  soft  tissue  origin  as  a  single
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entity.  Ewing’s  sarcoma  of  the  bone,  neuroepithelioma,  neu-
roblastoma  and peripheral  primitive  neuroectodermal  tumor
(PNET),  are neoplasms  included  in  this group,  and within  the
PNETs,  the Askin  tumor.3
According  to  medical  literature,  there  is  a greater  inci-
dence  in younger  patients.1--6 It presents  a  non-specific
clinical  behavior,  making  its  precise  diagnosis  difficult  in
its  early  stages.2--6 Its  high  rate  of  local  recurrence  and
the lack  of  clinical  guidelines  which  establish  a stan-
dardized  management  contribute  to  a less  than  favorable
prognosis  and  a short  survival  rate.4 Due  to  late  diag-
noses,  large  size  masses  are  found,  which  compromise
the  tumor’s  surgical  resection  because  of  the presence  of
adjacent  vital anatomic  structures.1 There  are,  however;
studies  proving  a higher  survival  rate  in  patients  treated
with  neoadjuvant  chemotherapy  followed  by  a surgical
approach  and  postoperative  radiotherapy.5,6 The  contribu-
tion  made by  Demir  et al. on  surgical  treatment  clarifies  the
http://dx.doi.org/10.1016/j.rmu.2015.09.003
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need  for  a  multimodal  management,  showing  that  induc-
tion  with  chemotherapy  contributes  to  tumor-free  resection
margins.5
Clinical  case
A  25-year-old  male  with  a background  of  active  smoking  (12
packs/year),  is  admitted  after  presenting  intermittent  pleu-
ritic  pain in  the left  hemithorax,  of  variable  intensity,  of
a  two-month  evolution;  accompanied  by  a non-productive
cough,  non-quantified  fever  and a 10  kg  weight  loss  in
a  course  of  three  months,  without  a history  of  occupa-
tional  exposure  hemoptysis  or  wheezing.  Patient  refers  to
have  received  a previous  ambulatory  treatment  with  sul-
famethoxazole/trimethoprim,  clindamycin  and  levofloxacin
for  7 days  without  improvement.  During  physical  examina-
tion,  we  observed  in a  central  trachea,  cylindrical  thorax
and  symmetric  respiratory  movements  without  the  use
of  accessory  muscles  and with  no  evident  or  palpable
masses.  At  auscultation,  a  reduced  vesicular  murmur  is
found  in  the  base  of  the left hemithorax,  with  no  clinical
data  added.  Blood  studies  were  within  normal  parame-
ters.  Thoracic  X-rays are performed,  where  a  radio-opacity
is  found  in the left hemithorax  with  effacement  of  the
costophrenic  angle  (Fig.  1).  Computed  contrasted  tomo-
graphy  of  the thorax  showed the presence  of  an extra
pulmonary  tumor (17.6  cm ×  12.6  cm  ×  11.3  cm),  dependent
on  soft  tissue  of the left  thoracic  wall,  extending  from
the  fourth  to  the  twelfth  posterior  costal  arches, with  a
heterogeneous  rise  of  the contrast  material,  without evi-
dence  of  mediastinal  adenopathies  (Fig.  2).  An  incisional
biopsy  is  performed  through  a left  posterolateral  thora-
cotomy  with  a trans-operatory  histopathological  report  of
a  slightly  differentiated  malignant  neoplasia.  Our  patient
courses  with  a post-operative  evolution  with  no  negative
eventualities.  After  performing  a  definite  histopatholog-
ical  analysis,  the presentation  of  a confirmed  primitive
neuroectodermal  tumor  through  the presence  of  small
round  cells is  described  (Fig.  3),  with  immunohistochem-
ical  markers  positive  for  FLI-1 and  CD99,  and  negative
for  cytokeratin,  vimentin,  TdT,  CD45,  CD43  and CD56,
Figure  1  Thoracic  X-ray  at  the  time  of admission.  Radiopacity
in the  left  hemithorax  is observed.
Figure  2  Contrasted  thoracic  CAT  scan.  Tumor  dependent  on
the soft  tissue  of  the  left  thoracic  wall.
Figure  3 Panoramic  view  at  5×  of  the  neoplasmic  lesion
composed of  small  cells,  round  and  blue,  between  septa  of
connective  tissue.
with a positive  flurosescence  in situ  hybridization  (FISH)
for  rearrangement  of  the EWSR1  gene  (Fig.  4). Oncologi-
cal  management  with  chemotherapy  is  started,  under  an
alternate  scheme  using:  vincristine  2  mg/m2,  doxorubicin
75  mg/m2,  cyclophosphamide  1200  mg/m2 (Day  1) with  ifos-
famide  1800  mg/m2 and  etoposide  100  mg/m2 (Day  1--5)
every  3 weeks,  dosage  dependent  on  patient’s  tolerance
under  radiographic  control  of  the tumor.  At  the  time  of  the
edition  of  this  article,  the patient  is  stable,  receiving  his
first  cytotoxic  cycle,  and  expecting  a reduction  in the size
of  the tumor,  thus  making  resection  of  the  lesion  possible.
Discussion
Despite  the advent  of  new  diagnostic  techniques  and  tools,
Askin  tumor  has  maintained  a  low  incidence  since  it was  first
described,  which  makes  us wonder  about  the factors  associ-
ated  with  the onset  of the responsible  genetic  mutation.
Tumors  of  the SE/PPNET  family are categorized  under
the  same  entity  because  of  the  common  histological
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Figure  4  Break  apart-type  FISH  test  for  the  rearrangement
of EWSR-1.  In  this  test,  2 red  signals  and  2  green  signals  can  be
observed.  The  test  is  positive  when  the  red  and  green  signals
are separated.
conformations  they  show,  differentiating  from  one another
by  their  degree  of  neuroectodermal  differentiation.  They
also  present  chromosomic  translocation  (11; 22)  (q24;  q12)
which  fusion  expresses  the gene  EWS/ETS  or  EWS/FL1.3
This  chimerical  gene is  observed  in  85%  of  SE/PPNET  group
tumors,  making  its  determination  a  crucial  tool  in  the
cytogenetic  diagnosis.7
Its  incidence  is  greater  in  males,  and 80%  of  diagnosed
patients  are  under  20  years  of age;  however,  there  are
reported  cases  of  elderly  patients.1 The  most  common
causes  of  death  are  associated  with  local  recurrence,  distant
metastases  and  infiltration  of  the  pulmonary  parenchyma.1,4
Among  the  most recent reports,  Contesso  et al.  showed  a
general  survival  rate  of  14%  at 6 years  and  a disease-free
survival  rate  of  17%  at 6 years.8
The  clinical  picture  usually  describes  ambiguous  symp-
toms  including:  a  palpable  mass  in  the thorax,  either  painful
or  painless  (the  most common  finding),1,9 pleuritic  pain,
dyspnea,  fever,  cough  and  weight  loss,  generally  of  insidi-
ous  onset  6 months  prior  to  diagnosis,  and,  less  frequently,
Horner’s  syndrome.1,2,8,10 The  lack  of  clinical  suspicion  often
leads  to  an erroneous  diagnostic  impression,  treating  the
patient  initially  as  a pleural  effusion.10 Unlike  the reports  of
a  classic  presentation,  in the  case  of  our  patient  we  did not
observe  a  palpable  mass  as  an initial  symptom,  despite  the
dimension  of  the tumor  mass.  Nevertheless,  it presents  the
characteristic  ambiguous  symptomatology  associated  with
the  chronic  evolution  of the  clinical  picture.  Furthermore,
we  point  out  the importance  of  considering  tumors  of  the
soft  tissue  of  the  thoracic  wall  within  the  differential  diag-
nosis  in those patients  whose  symptomatology  is  compatible
with  that  of  an unresolved  infectious  process.  Few studies
evaluating  the radiological  characteristics  of this  tumor  have
been  conducted.  However,  the aid of  a computed  tomogra-
phy  (CT)  scan  or  magnetic  resonance  imaging  (MRI)  is  crucial
to  determine  the  extent,  the  possible  pulmonary  invasion  of
the  tumor,  and invasion  of  local  and  distal  structures,  as
well  as  response  to  treatment.4 Findings  by  CT with  con-
trast  include:  a  soft-tissue-dependent  mass,  usually  >5  cm,
with  displacement  of the adjacent  structures,  accompanied
by  a  heterogeneous  rise  of the contrast  material.  The  pres-
ence  of  calcifications,  lymphadenopathies,  necrotic  areas
and  hemorrhages  are less  frequent  findings.  Regarding  the
MRI,  masses  of  intermediate  to  hyperintense  intensity  are
described,  located  in  T1  and  T2,  with  a heterogeneous
rise  when  contrast dye  was  applied  in the  necrotic  areas.
Although  Sabate  et al.  concluded  that  radiological  findings
in  a  CT and  MRI are  not  specific  and  are  indistinguishable
from  other  malignancies  of  the  thoracic  wall.4 Regarding  our
patient’s  imaging  assessment,  performing  a  systemic  review
of  the  thoracic  X-ray  was  highly  beneficial,  hence it  presents
an  homogeneous  radiopacity  with  clean  edges and  superior
convexity,  that  in retrospection  is  of  great  importance  when
there  is  suspicion  of  a thoracic  tumor.
The  periosteum  and soft  tissues  from  the  thoracic  wall
are  typically  involved,  with  extension  to  the pleura  and
pulmonary  parenchyma.1 There  are  reports  of  cases  with
distant  metastases  to  distal  long  bones,  bone  marrow,  liver
and  the central  nervous  system  (CNS).  The  neuroectoder-
mal  origin  of the  tumor  explains  the  invasion  of  sympathetic
chain  ganglia,  resulting  in atypical  presentations.10
Diagnostic  precision  is  unavoidable,  because  the choice
of  therapeutic  management  depends  on  it.  The  tumors  are
solid,  circumscribed,  opaque  brown  with  focal  areas  of
necrosis  and  hemorrhage.3 Histologically,  we  are able  to  find
the  demonstration  of  round, small,  slightly  differentiated
cells  organized  in strands.2 Also,  it is  possible  to  identify  the
presence  of  pseudorosettes  as  well  as  the absence  of  fixation
or  a  weak fixation  to  periodic  acid  Schiff  stains  (PAS). With
the  use  of electronic  microscopy,  we  are  able  to  observe  the
presence  of  neurosecretory  granules,  in  addition  to  under-
developed  cytoplasmic  organelles.11
The  immunohistochemistry  in this  tumor  in particular
provides  a definite  base  in the differential  diagnosis  in
relation  to  the variety  of  malignancies  within  the group
of  tumors  in round  and  small cells,  such  as:  neuroblas-
tomas,  rhabdomyosarcoma  and  non-Hodgkin’s  lymphoma,
chondrosarcoma  and retinoblastoma.11
The  neuroectodermal  origin  can  be confirmed  with  the
presence  of  immunohistochemical  markers  with  a posi-
tive  result  for  CD99,  FLI1, NSE  and  vimentin.  TdT,  CD45,
LCA,  EMA,  cytokeratin,  desmin  and actin  markers  must  be
included  in the immunohistochemical  panel in order  to  per-
form  an exclusion  of other  round-cell  malignancies.  CD99
(mic-2)  protein  is  found  in the cellular  membrane  consis-
tently  in neoplasms  of  neuroectodermal  SE/PPNETS  origin.
It is  highly  sensitive,  but  unspecific,  thus  it must  be used  as
a  complement  with  other  immunohistochemical  markers.12
Fluorescence  in  situ  hybridization  (FISH)  and  the  amplifi-
cation  of  genomic  particles  with  a polymerase  chain  reaction
(PCR) are necessary  as  complementary  tools for  chromo-
somic  translocation  detection  (11;22)  (q24;  q12),  which  is
present  in 95%  of  the cases  of  these  neoplasms.6 Despite
the fact that  there  is  no  standardized  study  algorithm,  in
our  patient,  different  diagnostic  modalities,  as  well  as  mul-
tidisciplinary  work,  were  included.  However,  similar  to  what
has  been  described,  the histopathological  report  was  con-
firmatory,  highlighting  the presence  of  small  round cells
and  immunohistochemical  markers  for  CD99,  with  the cor-
responding  stains,  which allows  us to  make  a diagnosis  by
exclusion,  as  well  as  the positive  FISH  for  the  rearrangement
of  the  EWS/FL1  gene identified  in this  case.
At  first,  the treatment  of  this  pathology  was  performed
through  a  surgical  approach.2 Even  when different  attempts
to  standardize  a  diagnostic  and  therapeutic  algorithm  have
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been  made,  trustworthy  studies  proposing  a definite  scheme
are  few.  Treatments  nowadays  are based  on  findings  which
have  marked  a  milestone  in multimodal  use,  including
neoadjuvant  chemotherapy  schemes  as  well  as  systemic
treatment  for  every  case,  in conjunction  with  local  therapy
based  on  surgical  resection  and/or  radiotherapy.1,6
The  choice  of these  treatment  modalities  is  based
on  each  patient  individually.  Neoadjuvant  chemotherapy
reduces  the  possibility  of  microscopic  residual  disease,
increases  the possibility  of  a complete  resection  and
increases  the  disease-free  survival  rate.5 Sirivella  et al.
place  an  emphasis  on  the  necessity  of  making  an early  stage
diagnosis  through  the use  of  a  fine  needle  biopsy,  before  any
surgical  resection.  They report  an extension  of  survival  free
of  disease  of  10  years  upon  implementing  the  use  of  neoad-
juvant  chemotherapy,  in up  to  84%  of  patients  whose  tumors
were  found  when  the disease  did  not present  metastatic
spread,  compared  to  those  who  presented  metastatic  spread
and  costovertebral  compromise,  who  showed  a survival  rate
of  33%  at 10  years.  Patients  who  showed a poor  response
to  chemotherapy  were benefitted  by  the use  of  local  radio-
therapy  with  the goal  of  reducing  the size  of  the  tumor.13
The  surgical  approach  is  essential  in  the  management  and
removal  of the tumor,  and facilitating  direct  radiotherapy
with  less  exposure.  Veronesi  et  al. made  a  summary  of the
benefits  of  applying  aggressive  neoadjuvant  chemotherapy
treatment  in comparison  to  postoperative  chemotherapy,
suggesting  that  there  is  a reduction  of  the  intraoperative
risk  of  tumor  rupture  and  dissemination  of  the  tumor  cells,
making  a  complete  surgical  resection  possible.14 Surgical
resection  following  neoadjuvant  chemotherapy  allows  neg-
ative  margins  of 71%, compared  to  the 37%  of  patients  who
are  subjected  to  surgery  as  an  initial approach.12
Surgical  strategy  should  consist  of  making  a radical
resection  of  the  tumor  mass,  including  the  costal  level
involved,  as  well  as  the  adjacent  inferior  or  superior  rib,
circumscribed  muscle  and  adherent  soft  tissue,  procuring
tumor-free  margins  of 3--4  cm,  and reconstructing  the tho-
racic  wall  with  flaps  or  muscular  tissue.12 In  cases  where
the  pulmonary  parenchyma  is  compromised,  a lobectomy
or pneumonectomy  should be  performed,  if  the case  merits
it.  The  importance  of a complete  surgical  resection  is  that
it  prolongs  disease-free  survival,  although  development  of
local  recurrences  will  remain  constant.5
The  chemotherapy  outlines  used  have  been  tested  in dis-
tinct  studies  with  the  intent  of homogenizing  an effective
treatment.  Outlines  similar  to  those  used  to  treat  Ewing’s
Sarcoma  have  been  used,  which  are  performed  through  the
use  of  vincristine  at  1.5--2 mg/m2, doxorubicin  at 40  mg/m2,
cyclophosphamide  at 1200  mg/m2 and  Actinomycin  D  at
1.25  mg/m2 (VACA)  or  vincristine,  adriamycin  and  ifosfamide
at  1800  mg/m2 and  Etoposide  at 100  mg/m2,  according  to  the
protocol  studied  at EICESS  92,  with  cycles  every  3 weeks.6,15
Radiotherapy  is  used as  an aid in the  local  control  of
the  primary  lesion,  posterior  to  surgical  resection,  with  the
aim  of  eliminating  any  fragment  of  the disease.  Treatment
should  be  directed  to  avoid  a dose  which would  damage  a
near  organ.  In  the CESS  81,  CESS  86  and  EICESS  92  studies,
the  use  of  postoperative  radiotherapy,  including  its  use  as
a  local  treatment,  showed  favorable  results  in relation  to
local  recurrence.  Currently,  the  dose  used  in radiotherapy  is
from  20  to  60  Gy.6,15
Diagnostic  age  has  been determined  in multiple  studies
to  be a  factor  in  a negative  prognosis,  considering  an  age
over  18  to  be  a  risk.  Poor  response  to  initial  chemotherapy
and  the presence  of  pleural  effusion  have  been  other  fac-
tors  associated  with  unfavorable  prognoses.1 Demir  et al.
observed  that  the  size  of the tumor and  the initial  response
to  treatment,  as  well  as  the  location  of  the tumor,  negatively
impacted  survival  rate.  An  osseous  or  pulmonary  origin,
or  a tumor  located  in the  costovertebral  union,  showed
decreased  survival  rates.5
The  importance  of  identifying  these  neoplasms  resides  in
its  aggressive  behavior  and in its high  rate  of recurrence.
Even  though  there  are  numerous  case  reports,  its  clinical
course,  diagnosis  and  treatment  are not very  clear.  There-
fore,  it  is  of  great  importance  that a multidisciplinary  team
is  familiar  with  these  tumors,  to  make  an adequate  correla-
tion  correlation  with  the  patient’s  history,  which  will  bring
us to  a better  understanding  of  its  behavior  and  establish  a
treatment  which  will  improve  the prognosis  and  survival  of
the  patient.
In  conclusion,  the  Askin  tumor  should  be considered
within  the differential  diagnosis  of thoracic  neoplasms.  Once
the diagnosis  of  a primitive  neuroectodermal  tumor  is  made,
optimal  treatment  will  consist  of  a multimodal  manage-
ment,  using  neoadjuvant  chemotherapy  in association  with
surgical  resection  and/or  postoperative  radiotherapy,  with
which  a  decreased  local  recurrence  and  a  greater  disease-
free  period  can  be  achieved.  Due  to  its  aggressive  behavior,
follow-up  of  these  patients  should  be performed  under  strict
adherence.
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